Genes and Immunity,
Год журнала:
2024,
Номер
25(2), С. 99 - 101
Опубликована: Март 13, 2024
While
chemotherapeutic
agents
were
long
solely
associated
with
immunosuppression,
clinical
data
demonstrate
that
the
combination
of
some
chemotherapies
immunomodulators
can
be
beneficial
against
cancer.
Defining
combinations
featuring
optimal
anticancer
activity
along
minimal
toxicity
remains
however
a
major
challenge.
Clinical
evidence
suggests
immune
responses
in
patients
treated
therapies
are
progression-free
survival.
Progress
understanding
mechanisms
responsible
for
following
chemotherapy
administration
facilitated
translation
relevant
chemoimmunotherapy
clinic.
CA A Cancer Journal for Clinicians,
Год журнала:
2023,
Номер
74(2), С. 187 - 202
Опубликована: Окт. 25, 2023
The
progression
of
cancer
involves
a
critical
step
in
which
malignant
cells
escape
from
control
by
the
immune
system.
Antineoplastic
agents
are
particularly
efficient
when
they
succeed
restoring
such
(immunosurveillance)
or
at
least
establish
an
equilibrium
state
that
slows
down
disease
progression.
This
is
true
not
only
for
immunotherapies,
as
checkpoint
inhibitors
(ICIs),
but
also
conventional
chemotherapy,
targeted
anticancer
agents,
and
radiation
therapy.
Thus,
therapeutics
stress
kill
while
provoking
tumor-targeting
response,
referred
to
immunogenic
cell
death,
useful
combination
with
ICIs.
Modern
oncology
regimens
increasingly
using
combinations,
chemoimmunotherapy,
well
combinations
multiple
However,
latter
generally
associated
severe
side
effects
compared
single-agent
Of
note,
success
these
combinatorial
strategies
against
locally
advanced
metastatic
cancers
now
spurring
successful
attempts
move
them
past
postoperative
(adjuvant)
setting
preoperative
(neoadjuvant)
setting,
even
patients
operable
cancers.
Here,
authors
critically
discuss
importance
immunosurveillance
modern
clinical
management.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Май 10, 2024
Cancer
immunotherapy,
such
as
immune
checkpoint
blockade
(ICB),
has
emerged
a
groundbreaking
approach
for
effective
cancer
treatment.
Despite
its
considerable
potential,
clinical
studies
have
indicated
that
the
current
response
rate
to
immunotherapy
is
suboptimal,
primarily
attributed
low
immunogenicity
in
certain
types
of
malignant
tumors.
Immunogenic
cell
death
(ICD)
represents
form
regulated
(RCD)
capable
enhancing
tumor
and
activating
tumor-specific
innate
adaptive
responses
immunocompetent
hosts.
Therefore,
gaining
deeper
understanding
ICD
evolution
crucial
developing
more
therapeutic
strategies.
This
review
focuses
exclusively
on
both
historical
recent
discoveries
related
modes
their
mechanistic
insights,
particularly
within
context
immunotherapy.
Our
findings
are
also
highlighted,
revealing
mode
induction
facilitated
by
atypical
interferon
(IFN)-stimulated
genes
(ISGs),
including
polo-like
kinase
2
(
PLK2
),
during
hyperactive
type
I
IFN
signaling.
The
concludes
discussing
potential
ICD,
with
special
attention
relevance
preclinical
settings
field
Immunotherapy
has
shaped
the
treatment
approach
to
diffuse
large
B-cell
lymphoma
(DLBCL),
with
rituximab
leading
remarkable
improvements
in
outcomes
for
both
relapsed
and
treatment-naïve
patients.
Recently,
groundbreaking
immunotherapies
like
chimeric
antigen
receptor
T-cells
have
entered
arena
relapsed/refractory
(R/R)
DLBCL
gained
regulatory
approval
several
countries.
The
concept
of
harnessing
a
patient's
own
combat
cancer
been
further
explored
through
development
bispecific
antibodies
(BsAbs),
class
engineered
antibody
products
designed
simultaneously
target
two
different
antigens.
These
novel
drugs
demonstrated
impressive
single-agent
activity
manageable
toxicity
patients
heavily
pretreated
non-Hodgkin
lymphoma.
In
this
review,
we
provide
an
up-to-date
overview
recently
completed
or
ongoing
BsAbs
trials
R/R
DLBCL,
including
results,
emerging
combination
data,
constructs.
Seminars in Liver Disease,
Год журнала:
2024,
Номер
44(02), С. 159 - 179
Опубликована: Май 1, 2024
Primary
liver
cancer,
represented
mainly
by
hepatocellular
carcinoma
(HCC)
and
intrahepatic
cholangiocarcinoma
(CCA),
is
one
of
the
most
common
deadliest
tumors
worldwide.
While
surgical
resection
or
transplantation
are
best
option
in
early
disease
stages,
these
often
present
advanced
stages
systemic
treatment
required
to
improve
survival
time.
The
emergence
immune
checkpoint
inhibitor
(ICI)
therapy
has
had
a
positive
impact
especially
on
cancers,
thereby
establishing
immunotherapy
as
part
first-line
HCC
CCA.
Nevertheless,
low
response
rates
reflect
usually
cold
immunosuppressed
tumor
microenvironment
primary
cancer.
In
this
review,
we
aim
summarize
mechanisms
resistance
leading
escape
with
special
focus
composition
both
CCA,
also
reflecting
recent
important
developments
ICI
combination
therapy.
Furthermore,
discuss
how
ICIs
established
cancer
treatments
(e.g.
multikinase
inhibitors
chemotherapy)
well
more
complex
combinations
state-of-the-art
therapeutic
concepts
may
reshape
microenvironment,
higher
long-lasting
antitumor
immunity
for
patients.
Cancer
vaccines
offer
an
exciting
option
for
active
immunotherapy,
providing
a
potentially
safe
and
effective
treatment
that
also
prevents
or
minimizes
toxic
side
effects
in
vaccinated
patients.
Clinical
results
from
previous
phase
III
clinical
trials
have
suggested
the
efficacy
of
cancer
largely
depends
on
their
potential
to
trigger
robust
immunological
responses.
A
preexisting
immune
response
cancer-specific
peptides
is
crucial
achieving
meaningful
outcome
during
vaccinations.
However,
various
factors
may
hinder
effectiveness
therapeutic
vaccines.
By
overcoming
these
challenges,
become
cornerstone
immunotherapy.
This
review
aims
share
our
insights
major
challenges
are
encountered
when
optimizing
vaccines,
particularly
focusing
important
aspects
regulating
efficacy,
such
as
vaccine
composition,
adjuvant
be
used
HLA-restricting
element
tumor
targeted
by
particular
vaccine.
Additionally,
we
discuss
several
obstacles
which
hindered
successful
development
standard
care,
design,
choice
antigen(s)
included
formulation.
The
identification
patients
most
likely
respond
vaccinations
developing
responses
desirable
crucial,
and,
therefore,
predictive
biomarkers
strictly
required.
Finally,
present
views
future
prospects
lead
enhancement
anticancer
ensuring
pivotal
role
